Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Diabetes & Metabolism Journal ; : 560-567, 2019.
Artículo en Inglés | WPRIM | ID: wpr-763690

RESUMEN

The link of diabetes with co-occurring disorders in the brain involves complex and multifactorial pathways. Genetically engineered rodents that express familial Alzheimer's disease-associated mutant forms of amyloid precursor protein and presenilin 1 (PSEN1) genes provided invaluable insights into the mechanisms and consequences of amyloid deposition in the brain. Adding diabetes factors (obesity, insulin impairment) to these animal models to predict success in translation to clinic have proven useful at some extent only. Here, we focus on contributing factors to diabetic brain injury with the aim of identifying appropriate animal models that can be used to mechanistically dissect the pathophysiology of diabetes-associated cognitive dysfunction and how diabetes medications may influence the development and progression of cognitive decline in humans with diabetes.


Asunto(s)
Humanos , Amiloide , Lesiones Encefálicas , Encéfalo , Demencia , Diabetes Mellitus , Insulina , Modelos Animales , Obesidad , Placa Amiloide , Presenilina-1 , Roedores
2.
Journal of Lipid and Atherosclerosis ; : 144-151, 2019.
Artículo en Inglés | WPRIM | ID: wpr-765671

RESUMEN

Type 2 diabetes (T2D) increases the risk for cerebrovascular disease (CVD) and dementia. The underlying molecular mechanisms remain elusive, which hampers the development of treatment or/and effective prevention strategies. Recent studies suggest that dyshomeostasis of amylin, a satiety hormone that forms pancreatic amyloid in patients with T2D, promotes accumulation of amylin in cerebral small blood vessels and interaction with Alzheimer's disease (AD) pathology. Overexpression of human amylin in rodents (rodent amylin does not form amyloid) leads to late-life onset T2D and neurologic deficits. In this Review, we discuss clinical evidence of amylin pathology in CVD and AD and identify critical characteristics of animal models that could help to better understand molecular mechanisms underlying the increased risk of CVD and AD in patients with prediabetes or T2D.


Asunto(s)
Humanos , Enfermedad de Alzheimer , Amiloide , Vasos Sanguíneos , Trastornos Cerebrovasculares , Demencia , Complicaciones de la Diabetes , Diabetes Mellitus Tipo 2 , Polipéptido Amiloide de los Islotes Pancreáticos , Modelos Animales , Manifestaciones Neurológicas , Patología , Estado Prediabético , Roedores
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA